FDA grants fast track status to Annexon’s ANX005 to treat Guillain-Barré Syndrome

This article was originally published here

GBS is a rare, acute and antibody-mediated autoimmune disease that will affect the peripheral nervous system. The disease currently has no approved therapies in the US. Earlier, the

The post FDA grants fast track status to Annexon’s ANX005 to treat Guillain-Barré Syndrome appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply